TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC
- PMID: 28935174
- DOI: 10.1016/j.prp.2017.08.012
TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC
Abstract
Background: Breast carcinomas (BC) belong to a heterogeneous group of malignant diseases. Correct categorization of BC based on molecular biomarkers has a very important role in deciding the proper course of therapy for each patient. It has been already shown that the decrease of TIMP metalloproteinase inhibitor 3 (TIMP-3) together with overexpression of microRNA-21 (miR-21) might be involved in the process of BC invasion. This is the first study that examined relationship among miR-21, TIMP-3 mRNA and TIPM-3 protein levels in BC groups formed according to invasiveness.
Methods: In this study, we used 46 breast cancer samples. Estrogen and progesterone receptor (ER, PR) protein levels were evaluated by immunohistochemistry (IHC) method. TIMP-3 mRNA expression was examined by two-step real-time quantitative PCR (qRT-PCR). Western blot analysis was performed for 16 samples.
Results: Statistically significant differences in TIMP-3 expression levels between invasive groups were discovered in ER positive (ER+) (p=0.015), Her-2 negative (p=0.026) subgroups, and patients without lymph-node metastasis (p=0.039). Interestingly, significant positive correlation was detected between miR-21 and TIMP-3 mRNA levels (P<0.001, ρ=0.949) in the group of in situ tumors. TIMP-3 mRNA expression levels highly negatively correlated with levels of miR-21 in PR+ invasive BCs (p=0.007, ρ=-0.641). TIMP-3 protein levels negatively correlated with miR-21 levels in pure invasive BCs.
Conclusion: These data suggest that signaling pathways involved in formation and progression of BCs in groups formed according to invasiveness might be different. Our findings propose that TIMP-3 mRNA expression levels could be significant prognostic parameter, but within specific BC subtypes.
Keywords: Breast cancer invasion; TIMP-3; miR-21.
Copyright © 2017 Elsevier GmbH. All rights reserved.
Similar articles
-
Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels.Mol Diagn Ther. 2016 Dec;20(6):603-615. doi: 10.1007/s40291-016-0230-3. Mol Diagn Ther. 2016. PMID: 27488105
-
MiR-4728-3p could act as a marker of HER2 status.Cancer Biomark. 2015;15(6):807-14. doi: 10.3233/CBM-150524. Cancer Biomark. 2015. PMID: 26406406
-
Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma.Oncol Rep. 2000 Jul-Aug;7(4):871-4. doi: 10.3892/or.7.4.871. Oncol Rep. 2000. PMID: 10854560
-
mRNA, microRNA and lncRNA as novel bladder tumor markers.Clin Chim Acta. 2018 Feb;477:141-153. doi: 10.1016/j.cca.2017.12.009. Epub 2017 Dec 7. Clin Chim Acta. 2018. PMID: 29224950 Review.
-
Proteomics-Based Identification of Dysregulated Proteins in Breast Cancer.Proteomes. 2022 Oct 21;10(4):35. doi: 10.3390/proteomes10040035. Proteomes. 2022. PMID: 36278695 Free PMC article. Review.
Cited by
-
Tissue inhibitor of matrix metalloproteinase-3 has both anti-metastatic and anti-tumourigenic properties.Clin Exp Metastasis. 2020 Feb;37(1):69-76. doi: 10.1007/s10585-019-10017-y. Epub 2020 Jan 1. Clin Exp Metastasis. 2020. PMID: 31894441 Review.
-
Assessment of prognostic value of tissue inhibitors of metalloproteinase 3 (TIMP3) protein in ovarian cancer.Libyan J Med. 2021 Dec;16(1):1937866. doi: 10.1080/19932820.2021.1937866. Libyan J Med. 2021. PMID: 34240668 Free PMC article.
-
Computational and in vitro analyses on synergistic effects of paclitaxel and thymoquinone in suppressing invasive breast cancer cells.Mol Biol Rep. 2024 Mar 6;51(1):388. doi: 10.1007/s11033-024-09328-5. Mol Biol Rep. 2024. PMID: 38446390
-
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?Int J Oncol. 2020 Jan;56(1):47-68. doi: 10.3892/ijo.2019.4920. Epub 2019 Nov 25. Int J Oncol. 2020. PMID: 31789396 Free PMC article.
-
miRNAs as Potential Treatment Targets and Treatment Options in Cancer.Mol Diagn Ther. 2018 Apr;22(2):157-168. doi: 10.1007/s40291-017-0314-8. Mol Diagn Ther. 2018. PMID: 29335927 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous